Targeting cardiovascular risk in patients with diabetes: Management of dyslipidemia

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 2, 2008, Pages 142-146

  Ali, Yasmine S ^a   Linton, MacRae F ^a   Fazio, Sergio ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherogenic lipid triad; Cardiovascular risk; Diabetes; Dyslipidemia

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; LIPOPROTEIN;

ADD ON THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETIC PATIENT; DRUG MEGADOSE; DYSLIPIDEMIA; HUMAN; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PREVENTION AND CONTROL; REVIEW; RISK FACTOR; BLOOD; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFECT;

CLINICAL TRIALS AS TOPIC; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; RISK FACTORS;

EID: 42449114912     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f5ff98     Document Type: Review

References (51)

1. Goff DC Jr, Gerstein HC, Ginsberg HN, et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99:4i-20i.
2. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007; 67:997-1026.
3. Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 2007; 120:S12-S17.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
5. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
7. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129:681-689.
8. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998; 98:2513-2519.
9. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
10. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106:2055-2060.
11. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517.
12. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-418.
13. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861.
14. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Bmj 1998; 316:823-828.
15. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
16. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005; 5:379-387.
17. Hobbs FD. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. Int J Cardiol 2006; 110:137-145.
18. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care 1991; 14:839-855.
19. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70:3H-9H.
20. Assmann G, Schulte H. The Prospective Cardiovascular Munster Study: prevalence and prognostic significance of hyperlipidemia in men with systemic hypertension. Am J Cardiol 1987; 59:9G-17G.
21. Hollenbeck CB, Chen YD, Greenfield MS, et al. Reduced plasma high-density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1986; 62:605-608.
22. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 (Suppl):S11-S20.
23. Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004; 45:948-953.
24. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104:1108-1113.
25. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
26. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301-1310. This posthoc analysis of the TNT study showed that HDL cholesterol levels remained predictive of major adverse cardiovascular events even at LDL levels below 70 mg/dl in patients treated with statins.
27. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
28. Robins SJ, Collins D, Wittes JT, et al., VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial: relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585-1591.
29. Davidson MH, Stein EA, Bays HE, et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29:1354-1367. The efficacy and safety of omega-3 fatty acids in addition to moderate-dose simvastatin is demonstrated in 254 patients followed for a total of 16 weeks.
30. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
31. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
32. Armitage J. The safety of statins in clinical practice. Lancet (in press).
33. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-732.
34. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007; 49:1753-1762. The authors review the specific individual patient characteristics that may increase risk of statin toxicity, including age, sex, comorbidities, and drug interactions.
35. Gotto A, Pownall H. Lipid-regulating drugs and low-density lipoprotein apheresis. In: Manual of lipid disorders: reducing the risk for coronary heart disease. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. pp. 332-348.
36. Raal F, Schamroth C, Patel J, Becker P. A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr 2007; 18:325-329. This article validates the consistent LDL-lowering effect of ezetimibe when added to statin therapy in a population differing from the general American population in terms of dietary habits, lifestyle changes, and ethnic composition.
37. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29:74-83. This important pilot study demonstrated beneficial effects beyond lipid lowering, especially glucose-lowering effects, with the use of a common bile acid sequestrant in patients with inadequately controlled type 2 diabetes.
38. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99:22C-31C.
39. Coronary Drug Project Research Group. The coronary drug project. Design, methods, and baseline results. Circulation 1973; 47:I1-I50.
40. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998; 82:29U-34U; discussion 39U-41U.
41. Barter PJ, Caulfield M, Eriksson M, et al. ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122. This trial showed the surprising result of increased morbidity and mortality in high-risk patients treated with a potent CETP inhibitor, torcetrapib, designed to increase HDL levels. The mechanism of this increased risk is as yet unknown.
42. Kastelein JJ, van Leuven SI, Burgess L, et al. RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620-1630.
43. Nissen SE, Tardif JC, Nicholls SJ, et al. ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316.
44. Bots ML, Visseren FL, Evans GW, et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007; 370:153-160.
45. Brown BG, Boden, WE. ClinicalTrials.gov. Niacin plus statin to prevent vascular events. ClinicalTrials.gov identifier: NCT00120289. http://clinicaltrials.gov/ct/show/NCT00120289. [Accessed 30 November 2007]
46. Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs 2007; 67:121-153. This is an excellent review of the use of fenofibrate for multiple indications.
47. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-910.
48. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:2-4.
49. Tenkanen L, Manttari M, Kovanen PT, et al. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 2006; 166:743-748. This is an 18-year update of the Helsinki Heart Study, revealing that patients with atherogenic dyslipidemia in particular benefited most when gemfibrozil was started early.
50. Ginsberg HN, Bonds DE, Lovato LC, et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99:56i-67i.
51. Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447:959-965.